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and James G Taylor VI2*
Abstract
Background: Sleep disturbance and depression are commonly encountered in primary care. In sickle cell disease,
depression is associated with pain, poor treatment compliance, and lower quality of life. The prevalence of sleep
disturbance and its effect upon quality of life in adults with sickle cell disease is unknown. The goal of this study
was to determine the prevalence of sleep disturbance and if it is associated with pain and depression in sickle cell
disease.
Methods: Three hundred twenty eight adults with sickle cell disease enrolled on the Bethesda Sickle Cell Cohort
Study were assessed using the Pittsburgh Sleep Quality Index and Beck Depression Inventory II screening measures
as a cross-sectional survey. Scores greater than 5 (Pittsburgh Sleep Quality Index) and 16 (Beck Depression Inventory
II) defined sleep disturbance and depression, respectively. Clinical and laboratory parameters were also assessed.
Results: The mean Pittsburgh Sleep Quality Index score was 8.4 (SD ± 4.2) indicating a 71.2% prevalence of sleep
disturbance. The mean Beck Depression Inventory II score was 8.0 (SD ± 8.9). Sixty five (20.6%) participants had a
score indicating depression, and half of these (10.0%) had thoughts of suicide. Both Pittsburgh Sleep Quality Index and
Beck Depression Inventory II scores were significantly correlated (p < .001). The number of days with mild/moderate
pain (p = .001) and a history of headaches (p = .005) were independently associated with depression by multivariate
regression analysis. Patients with sleep disturbance were older (p = .002), had higher body mass index (p = .011), had
more days of pain (p = .003) and more frequent severe acute painful events (emergency room visits and
hospitalizations) during the previous 12 months (p < .001).
Conclusions: More than 70 percent of adults with sickle cell disease had sleep disturbance, while 21 percent showed
evidence of clinical depression. Sleep disturbance and depression were correlated, and were most common among
those with more frequent pain. Providers caring for adults with sickle cell disease and frequent pain should consider
screening for these common co-morbidities. Additional study is needed to confirm these findings and to determine if
treatments for pain, depression or sleep disturbances will improve quality of life measures in this patient population.
Trial registration: ClinicalTrials.gov identifier: NCT00011648.
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Background
Sickle cell disease (SCD) is a recessive genetic disorder
caused by mutations in the β-hemoglobin gene on
chromosome 11. It affects an estimated 100,000 people in
the United States, making it among the most common
rare diseases in this country [1,2].
The pathophysiological basis for the clinical manifesta-
tions of SCD is polymerization of deoxygenated sickle
hemoglobin within the red blood cell, which promotes red
cell rigidity and initiates a cascade of events obstructing
blood flow in post-capillary venules known as vaso-
occlusion. Sickle cell vaso-occlusion can produce intense
acute pain, presumably due to tissue hypoxia secondary to
obstructed blood flow [3]. Acute, severe painful episodes
often necessitate hospitalization for pain management
with intravenous opioids. Variability is observed among
SCD patients for both the frequency and severity of
these painful episodes [4]. In addition to pain, SCD is
characterized by chronic organ damage, hemolytic anemia
and premature mortality [3].
Depressive disorders, sleep disturbance and fatigue are
proposed to be key variables in a biobehavioral model of
SCD [5]. Cognitive behavioral processes such as depres-
sion and catastrophizing contribute to variation in pain
perception and are hypothesized to play a role in pain
modulation [6]. The prevalence of depression in SCD
ranges from 18 to 44% in adults [7-10], which is sub-
stantially higher than an overall prevalence of 9% across
the United States [11]. Depression in SCD is associated
with greater daily pain, lower quality of life measures,
and poor adherence to treatment regimens. Sleep dis-
turbance may be associated with serious, high morbidity
SCD complications [12-14], although it is also a well
described risk factor for major depression in otherwise
healthy individuals [15]. Despite a higher prevalence of
high morbidity sleep disturbances like obstructive sleep
apnea in SCD, this work has largely focused on children
with SCD [12-14,16,17]. As with depression, vaso-occlusive
pain crises further exacerbate disturbed sleep and daytime
functioning in SCD [18]. In addition, high somatic
symptom burden (SSB) in SCD is associated with
more non-crisis pain and healthcare utilization by patients
seeking symptomatic pain relief. High SSB is also associ-
ated with depression, anxiety and poorer health related
quality of life [19]. Importantly, the prevalence of sleep
problems and their relationship to depression have not
been defined in adults with SCD.
The objective of this study was to determine the
prevalence of sleep disturbance and the nature of the
relationships between depression, sleep disturbance and
associated factors defined by patient reported outcomes
in a cross-sectional sample of adults with SCD. We used
a conceptual explanatory model of pain and healthcare
utilization to determine if a relationship exists between
disease-related variables, markers of SCD pain, sleep
disturbance and depression. Smith and colleagues
developed this model of pain and utilization in SCD
to examine the relationship of individual demographics,
disease-related variables, and psychosocial variables, and
their effects on distress disability, healthcare utilization,
and pain [20]. For a variety of social and financial reasons,
the care of adults with SCD is often provided by primary
care physicians [21] who may be ideally suited for
screening and treating quality of life co-morbidities




Three hundred twenty eight subjects undergoing evaluation
on a protocol for evaluation of SCD (the Bethesda
Sickle Cell Cohort Study; ClinicalTrials.gov identifier
NCT00011648) were asked to complete survey instruments
as part of a cross sectional sub-study to assess mood and
sleep quality during an outpatient evaluation at the NIH
Clinical Center between June, 2009 and July, 2012. Survey
participants were either 1) undergoing an initial evaluation
at NIH or 2) returning for a follow-up evaluation where
subjects repeat the same clinical evaluation at regular 2 year
intervals from the date of initial protocol enrollment.
Those participating in the survey during 2 year follow-up
evaluations were originally enrolled on the Bethesda Sickle
Cell Cohort Study between March, 2001 and May,
2008 (a total of 488 subjects were enrolled at that
time). Subjects were evaluated in steady state without
an acute event in the 2 weeks prior to evaluation.
This protocol was approved by the National Heart,
Lung and Blood Institute Institutional Review Board. All
subjects provided written informed consent according to
the Declaration of Helsinki.
This sub-study was powered to detect associations
with depression where a given factor would double the
risk for depression. Assuming a 20% prevalence of
depression in SCD [7], a survey of 300 subjects would
give 80% power to detect associations of this magnitude
at a 1 sided type I (α) error rate of 0.05. Power estimates
were not made for sleep disturbance, as its prevalence
was unknown in this disease population.
Clinical history and measures
Subjects completed a medical history survey of patient
reported outcomes, with specific inquires about common
SCD complications including episodes of acute chest
syndrome (ACS) and stroke. Current medications were
obtained by patient history. For this study, current
narcotic use was defined as either daily sustained release
narcotic pain medication use or as needed narcotic pain
medication use for acute pain relief during the past
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month. Clinical evaluation included a physical exam, pulse
oximetry and standard laboratory testing. The diagnosis of
SCD was established by either DNA sequencing or high
performance liquid chromatography/clinical history and
was further sub-typed as homozygous SS, combination of
Hb S with β-thalassemia-zero (HbSβ0; generally severe) or
compound heterozygous SCD (generally clinically milder;
including HbS with HbC (HbSC) or β-thalassemia-plus
(Sβ+) [22,23].
Self-reported pain survey, mood and sleep quality
measures
Patients completed a self-reported survey of the number
of painful events attributed to SCD during the 12 months
prior to evaluation. This survey included 4 pre-defined
categories of painful episodes: mild, moderate, severe
and extremely severe. Pain episodes were classified as
“mild” when the participant reported experiencing pain
that did not prevent normal activities and may or may
not have required pain medication. A “moderate”
episode required pain medication and disrupted normal
daily activities (e.g. missed work). Episodes which required
an emergency department visit without hospitalization
were classified as “severe”. “Extremely severe” acute
painful events were the painful episodes which lead
to inpatient hospitalizations.
The Beck Depression Inventory (BDI-II) screens for
the presence and severity of depression in adults [24].
Each of the 21 BDI-II items queries a particular aspect
of depression. Individual items are rated on a 4 point
intensity scale rather than on a frequency dimension. A
rating of 3 indicates most severe intensity, while 0
indicates the absence of a problem. Thus, the greater the
score, the more depressed the individual [25]. BDI-II has
been validated in elderly adults with internal consistency
(α = 0.91) and predictive validity reported to be high
(0.85) [26]. Cut-off scores for depression vary by study
with scores between 14 and 17 indicating mild depres-
sion and scores ≥20 indicating severe depression [7,8].
In SCD, Asnani and colleagues chose a BDI-II cut-off
score of 17 rather than 14 because they found that the
higher score would produce greater specificity [7]. A
BDI-II cut-off score of ≥17 was also used for this
study to define depression. Subjects reporting suicidal
thoughts on the BDI survey were evaluated by a
psychiatrist or social worker during the clinic visit.
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated
questionnaire which provides a measure of sleep quality
and disturbances over a month time interval. Nineteen
survey items generate seven “component” scores: subjective
sleep quality, sleep latency, sleep duration, habitual sleep
efficiency, sleep disturbances, use of sleep medications, and
daytime dysfunction. Buysse et al. reported a global PSQI
score > 5 had a sensitivity of 89.6% and specificity of 86.5%
(kappa = 0.75, p < .001) in distinguishing subjects with good
sleep quality from those with poor sleep [27].
Statistical analysis
Associations with sleep quality or depression were
first examined by dichotomizing subjects into either a
depression group (BDI-II score ≥ 17) or a sleep disturbance
group (PSQI score ≥ 6) at thresholds previously shown to
be predictive of depression and poor sleep, respectively
[7,27]. Demographic, clinical, and laboratory characteristics
were compared between depressed subjects and subjects
without depression using the non-parametric Wilcoxon
rank-sum test for continuous variables and Pearson
chi-square for categorical variables. Comparisons were
made between low and high sleep disturbance groups.
Characteristics for analysis were chosen a-priori based
on hypothesized associations with pain and sleep in
SCD including age, body mass index, frequent headaches,
acute chest syndrome and acute painful episodes. Analysis
of variance was used to examine associations of BDI-II
and PSQI scores with the number of self-reported pain
episodes categorized into three groups. Then analysis of
covariance was used to examine these associations in
multivariate models while adjusting for other factors. For
all analyses, covariates were log-transformed as necessary
to reduce the influence of outlying values and to meet
normality assumptions of the statistical models. Statistical
models using different combinations of covariates
were generated for multivariable analyses, although
only statistically significant variables were presented
in the final models. P-values ≤ .050 were considered
significant. All analyses were performed using SAS
version 9.1.3 (SAS Institute Inc, Cary, NC), Stata version
9.0 (StatCorp LP, College Station, TX) and SVS (Golden
Helix, Bozeman, MT).
Results
A total of 328 subjects met criteria for inclusion from
329 surveyed. These 328 subjects represented 50% of the
654 potentially eligible participants enrolled in the
Bethesda Sickle Cell Cohort Study during the period of
the survey. One subject was excluded from analysis after
screening because of a diagnosis of sickle cell trait. One
hundred sixty six (51%) completed the surveys at study
entry and 162 (49%) did so at a protocol follow-up visit
(median time on study 4.7 years, interquartile range
(IQR) 2.3 - 7.8) (Figure 1). Follow-up visits were from a
pool of 488 subjects enrolled on the Cohort study at the
time the survey sub-study was initiated, with 33% of the
original cohort completing surveys (162/488). Overall, the
population had an even sex distribution (51% female), 277
(85%) with a diagnosis of SS or Sβ0 thalassemia and 155
(47%) reported taking hydroxyurea. The median age at the
time of surveys was 34 years (IQR 27 – 46), although 67
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subjects (20%) were 50 years of age or older. Subjects
reported a median of 13.0 (IQR 2.0 -80.0) mild to
moderate acute pain days and 2.0 (IQR 0.0 – 6.0) severe
to extremely severe pain events over the 12 months prior
to evaluation.
Depression and sleep disturbance were present in our
survey population (Table 1). Three hundred fifteen
subjects (96% of sample population) completed a
BDI-II survey with a median score of 8 (IQR 4–15).
Sixty five (21%) had scores suggestive of depression,
including 32 (10%) with suicidal thoughts (BDI-II item 9)
(Table 1). Three hundred thirteen PSQI surveys were
completed (95% of sample population) with a median
score of 9 (IQR 5–11). Two hundred twenty three subjects
(71%) had some degree of sleep disturbance (Table 1).
All subjects with sleep disturbance reported difficulty
sleeping due to pain (PSQI item 5i).
For those completing both surveys (n = 302), BDI-II
and PSQI scores were significantly correlated (Spearman
r = 0.51, p < .001) (Figure 2). Comparison of median
scores by Wilcoxon rank-sum gave a comparable result
(p < .001, data not shown), where 97 percent (n = 60
of 62) reporting symptoms of depression also had
poor sleep.
The clinical characteristics of subjects grouped into
BDI-II depression and PSQI sleep disturbance groups
Figure 1 Summary of the Pittsburgh Sleep Quality Index (PSQI)/Beck Depression Inventory II (BDI-II) cross-sectional surveys administered
during visits for the Bethesda Sickle Cell Cohort Study.
Table 1 BDI-II Depression and PSQI Sleep Scores in Adults
with Sickle Cell Disease
BDI-II SCD Population (n = 328)
Surveys completed, n (%) 315 (96)
Median (IQR) 8 (4–15)
Score≥ 17, n (%) 65 (21)
Suicidal thoughts, n (%) 32 (10)
PSQI
Surveys completed, n (%) 313 (95)
Median (IQR) 9 (5–11)
Score≥ 6, n (%) 223 (71)
Trouble sleeping due to pain, n (%) 235 (75)
Figure 2 Correlation between Pittsburgh Sleep Quality Index
(PSQI) and Beck Depression Inventory II (BDI-II) survey scores.
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were then compared to subjects without depression or
sleep disturbance, respectively (Table 2). The BDI-II
depression group (n = 65) had a significantly higher
prevalence of headaches (p = .007), more days of mild/
moderate pain (p = .040), more severe/extremely severe
pain events (p = .009) and lower hemoglobin (p = .050)
than the non-depressed group (Table 2). Similar associations
were observed for the sleep disturbance group with PSQI
scores ≥ 6 (n = 223) with more prevalent headaches
(p < .001), mild/moderate pain (p < .001) and severe/
extremely severe painful events (p < .001) (Table 2).
In addition, those in the sleep disturbance group
were significantly older (p = .009) and had higher body
mass index (BMI, 24 versus 23, p = .016). There were no
significant differences in hydroxyurea treatment, narcotic
use or percentage fetal hemoglobin when comparing
either the depression group or the sleep disturbance group
to their respective reference groups (Table 2).
The association between sleep disturbance and acute
SCD painful events appeared plausible based upon the
uniform response to PSQI item 5i (difficulty sleeping
due to pain, Table 1) and a higher median number of
severe or extremely severe acute painful events in those
with PSQI scores ≥6 (p < .001, Table 2). Further scrutiny
of this association showed that pain groups defined by
the number of severe and extremely severe acute painful
episodes had higher mean PSQI scores with increasing
numbers of acute painful events (p < .001, Table 3).
Increasing mean scores using the BDI-II were also
associated with more frequent severe/extremely severe
acute painful events (p < .001, Table 3). Analysis of
covariance including variables that were significantly
associated with BDI-II scores in Table 2, revealed only
days of mild/moderate acute pain and a history of
headaches were independently associated with higher
BDI-II scores (Table 4). A second multivariable analysis of
significant variables associated with the sleep disturbance
group in Table 2 showed acute painful events (both days
of mild +moderate pain and severe + extremely severe
pain events), increasing age and BMI were independently
associated with higher PSQI scores (Table 5).
Discussion
This is the first study documenting a high prevalence of
sleep disturbance in a cross sectional sample of unselected
adults with SCD and the relationship between disordered
sleep and depression. These findings suggest that while
physical symptoms of SCD, including pain and end organ
damage, are the primary clinical focus of providers in
outpatient clinics and emergency departments, disrupted
sleep architecture and depression are also co-morbid
diagnoses in SCD.
Depression and sleep disturbances have been associated
with adverse disease trajectories in children and adults
[10,28]. Although both of these studies assessed depres-
sion using the Patient Health Questionnaire and the SF-36
rather than a depression screening instrument, our find-
ings in adult SCD patients attending an ambulatory clinic
Table 2 Clinical Characteristic Comparisons by BDI-II Depression and PSQI Sleep Disturbance Groups
Demographic Variables BDI < 17 BDI ≥ 17 p1 PSQI < 6 PSQI ≥ 6 p1
N Median (IQR) 2 N Median (IQR) 2 N Median (IQR) 2 N Median (IQR) 2
Age 250 34 (27–47) 65 35 (27–45) .95 90 31 (23–45) 223 36 (29–47) .009
BMI (kg/m2) 245 24 (22–27) 63 24 (21–27) .12 89 23 (20–27) 217 24 (22–28) .016
Female, N (%) 250 119 (48) 65 40 (62) .052 90 42 (47) 223 118 (53) .32
SS/Sβ0 thalassemia, N (%) 250 212 (85) 65 53 (82) .57 90 78 (87) 223 184 (83) .40
Clinical History
Headache, N (%) 250 92 (37) 64 36 (53) .007 90 24 (27) 222 105 (47) <.001
Stroke, N (%) 230 32 (14) 56 6 (11) .66 81 14 (17) 204 23 (11) .18
Acute Chest Syndrome, N (%) 248 201 (81) 65 52 (80) .86 90 70 (78) 223 184 (83) .34
Hydroxyurea therapy, N (%) 250 120 (48) 65 31 (48) >.99 90 42 (47) 223 106 (48) .90
Mild + Moderate Pain (days) 244 11 (2–72) 60 25 (4–126) .040 88 4 (2–24) 214 23 (4–120) <.001
Severe + Extreme Pain (events) 250 2 (0–5) 65 3 (0–10) .009 90 0 (0–2) 223 3 (0–9) <.001
Current Narcotic Use, N (%) 250 159 (64) 65 47 (72) .24 90 53 (59) 223 153 (69) .11
Laboratory Measures
Hemoglobin (g/dL) 250 9.1 (7.8-10.4) 65 8.5 (7.4-9.8) .050 90 9.3 (8.1-10.4) 223 8.9 (7.6-10.3) .20
Hemoglobin F (%) 250 5.7 (1.9-12.5) 65 6.0 (3.1-10.7) .97 90 5.1 (1.8-13.2) 223 6.0 (2.7-11.7) .76
Oxygen Saturation (%) 248 97 (95–99) 65 97 (95–99) .97 89 98 (96–99) 222 97 (95–99) .093
1Pearson’s chi-square or Fisher’s exact test for categorical comparisons; Wilcoxon rank-sum for comparison of medians.
2Unless otherwise indicated.
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are similar, in that approximately one quarter (27.6%) of
their sample were ‘depressed’ while 13.8% had major
depression. We observed subjects with depression had
significantly more self-reported severe pain events (i.e.
emergency room visits and hospitalizations). Interestingly,
the Pain in Sickle Cell Epidemiology Study (PiSCES) ob-
served that patients with depression had pain on signifi-
cantly more days than non-depressed participants [10].
Our findings in adults with SCD support the premise
from Dampier and colleagues in the Comprehensive
Sickle Cell Centers (CSCC) Clinical Trial Consortium
(CTC) study of health-related quality of life (HRQOL),
namely that improved treatments for pain and depression
may provide the largest HRQOL benefit [29]. Further-
more, it remains unclear if improved SCD pain manage-
ment alone will have a cause and effect relationship
to lower the prevalence of depression.
Importantly, we also found that poor sleep is very
common and associated with both depression and more
frequent pain. There was a significant relationship
between subjects reporting PSQI defined poor sleep and
those reporting five or more episodes of severe or
extremely severe pain episodes in the previous year. BMI
was also independently associated with sleep disturbance
in this cohort. Previous studies have described the rela-
tionship between sleep fragmentation, impaired energy
metabolism and BMI [30,31]. The relationship between
obstructive sleep apnea and BMI has been well docu-
mented [31], yet this relationship has not been studied in
SCD. Obesity was not an overall concern in this study
with a median BMI of 24 in sleep disturbed subjects,
however the significant association between BMI and sleep
disturbance may provide areas for further categorization
and exploration of associations in future studies. Whether
the association between BMI and sleep disturbance in
our SCD cohort promotes sleep disturbance or is a
consequence of disordered sleep will require further
investigation.
As expected, nearly all subjects in our sample who were
depressed also reported poor sleep (97%), consistent with
sleep disturbance as a symptom of depression. It is inter-
esting to note that, despite the fact that 64.6% of our
sample reported chronic narcotic use, self-reported opioid
use was not significantly correlated with depression or
poor sleep. These findings support previous studies in
chronic pain patients without SCD which suggested poor
sleep may lead to a more painful day [32,33]. Overall,
these data suggest that SCD patients with sleep problems
should be screened for depression.
Despite using a set of classical biomarkers associated
with SCD severity, only anemia was associated with higher
risk for depression (Table 2). Hemoglobin, hematocrit and
fetal hemoglobin levels are traditional markers associated
with modulating the frequency of SCD pain crises [4].
However, the association between depression and anemia
just met criteria for significance, suggesting that the
magnitude of this effect is relatively small compared to the
association of higher hematocrit with vaso-occlusive pain
[4]. None of these parameters were associated with sleep
disturbances. Overall, we advocate for universal depres-
sion and sleep disturbance screening in adults with SCD,
irrespective of genotype (i.e. SS vs. SC) or disease severity.
Neurobiological sleep signaling could potentially be
disrupted by frequent antidepressant and narcotic treat-
ment in SCD. Selective serotonin reuptake inhibitors
(SSRIs) increase extracellular levels of serotonin while
tricyclic antidepressants increase the extracellular levels
of serotonin and norepinephrine; both decrease REM
sleep [34]. The effect of opioids on sleep architecture is
also important to consider since management of pain
crisis and chronic pain in sickle cell patients requires
variable regimens of narcotics for pain management.
Studies have shown that even single doses of oral opioid
medications can affect sleep architecture in healthy
adults by substantially decreasing their time in deep
sleep, stages 3 and 4; while increasing periods of light
sleep (stage 2) [35]. Because 65% of the subjects in our
study were taking chronic narcotics at the time of the
survey, this may contribute to the high prevalence of
sleep disturbance in SCD.
Table 3 Higher BDI-II and PSQI Survey Scores Associated
with More Frequent Severe SCD Painful Events
Severe + extremely severe
pain events Last 12 months
BDI-II Score PSQI Score
Mean (95% CI) Mean (95% CI)
0 8.8 (7.4-10.3) 7.6 (6.8-8.3)
1-4 10.4 (8.5-12.3) 8.2 (7.4-9.0)
5 or more 13.1 (11.2-14.9) 10.3 (9.5-11.0)
p1 <.001 <.001
1From ANOVA F-test for comparison of more than 2 groups.
Table 4 Independent variables associated with positive
screening for depression in SCD
Variable F (df) p
Mild + Moderate Pain (days)1 10.93 (1,301) .001
History of Headaches 8. 17 (1,301) .005
1Transformed using the natural log function.
Table 5 Independent variables associated with positive
screening for sleep disturbance in SCD
Variable F (df) p
Mild + Moderate Pain (days)1 9.09 (1,290) .003
Severe + Extreme Pain (events) 1 15.62 (1,290) <.001
Age (years) 9.39 (1,290) .002
BMI (kg/m2)1 6.55 (1,290) .011
1Transformed using the natural log function.
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These data should be interpreted with several caveats.
First, data collected in these survey instruments were
patient reported outcomes and not objective mea-
sures of depression and sleep quality. If discrepancies
exist between self-reported and objective measures,
these differences will need to be adjusted so that the
associations between sleep and other psychosocial
factors are not overestimated [36]. Furthermore, our
cross-sectional analysis did not include a measure of
somatization which may be a confounding variable
in assessing the prevalence of depression in this
population. Studies now suggest that somatization,
an overwhelming attention to bodily symptoms, in
SCD patients is predictive of negative psychological
outcomes including depression, anxiety and hostility
[19,37].
Conclusion
Overall, 71% of adults with SCD surveyed reported sleep
disturbance, and one in five were depressed. Sleep dis-
turbance and depression assessed by surveys show a
moderate correlation (r = .51) and were more common
among those with more frequent painful episodes.
These findings need to be confirmed by more direct
measurements of sleep architecture. Additional study
is needed to determine if treatment of pain, depres-
sion or sleep disturbance can improve outcomes or
health related quality of life in adults with SCD. Providers
caring for adults with SCD and frequent pain should
consider screening for these common co-morbid
conditions.
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